

### Claim Amendments

The following amendments include the cancellation of claims 47 and 49.

1-45 (canceled)

46 (currently amended): A method of determining whether a drug or compound is effective against *Mycobacterium tuberculosis* comprising:

(a) transforming, ~~into~~ a mycobacterium[[,]] with a vector construct comprising a ~~nucleotide sequence of a~~ *Mycobacterium tuberculosis* iniB promoter inserted into a plasmid;

(b) culturing the mycobacterium;

(c) treating the cultured mycobacterium with the drug; and

(d) measuring induction of the iniB promoter, wherein the induction of the iniB promoter causes expression of a reporter gene, and wherein the presence of induction ~~indicating~~indicates the drug is effective against *Mycobacterium tuberculosis*.

47 (canceled)

48 (previously presented): The method of claim 46, wherein the mycobacterium is selected from the group consisting of *Mycobacterium tuberculosis*, *Mycobacterium avium*, *Mycobacterium smegmatis*, *Mycobacterium bovis* BCG, *Mycobacterium leprae*, *Mycobacterium africanum*, and *Mycobacterium intracellulare*.

49 (canceled)

50 (currently amended): The method of claim [[49]]46, wherein the reporter gene is selected from the group consisting of lacZ and luciferase.

51 (previously presented): The method of claim 46, wherein the drug or compound is effective against the biosynthesis of the *Mycobacterium tuberculosis* cell wall.

52 (previously presented): The method of claim 46, wherein the nucleotide sequence of the iniB promoter comprises SEQ ID NO:1 and nucleotides 1-159 of SEQ ID NO:2.